Applied Genetic Technologies (AGTC) Releases Quarterly Earnings Results, Beats Estimates By $0.41 EPS

Share on StockTwits

Applied Genetic Technologies (NASDAQ:AGTC) issued its earnings results on Thursday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.41, MarketWatch Earnings reports. The company had revenue of $5.93 million for the quarter. Applied Genetic Technologies had a negative net margin of 61.04% and a negative return on equity of 18.77%.

Shares of NASDAQ:AGTC opened at $3.38 on Friday. The company has a market capitalization of $61.28 million, a P/E ratio of -2.86 and a beta of 2.76. Applied Genetic Technologies has a fifty-two week low of $2.26 and a fifty-two week high of $7.50.

Large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its position in shares of Applied Genetic Technologies by 11.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 817,584 shares of the biotechnology company’s stock valued at $5,968,000 after acquiring an additional 85,686 shares during the period. Renaissance Technologies LLC raised its position in shares of Applied Genetic Technologies by 11.5% in the 3rd quarter. Renaissance Technologies LLC now owns 707,500 shares of the biotechnology company’s stock valued at $5,165,000 after acquiring an additional 73,000 shares during the period. Wells Fargo & Company MN raised its position in shares of Applied Genetic Technologies by 9,001.3% in the 3rd quarter. Wells Fargo & Company MN now owns 215,610 shares of the biotechnology company’s stock valued at $1,574,000 after acquiring an additional 213,241 shares during the period. Finally, Vanguard Group Inc raised its holdings in Applied Genetic Technologies by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 494,618 shares of the biotechnology company’s stock worth $3,611,000 after buying an additional 5,300 shares during the period. Institutional investors and hedge funds own 44.24% of the company’s stock.

A number of brokerages recently weighed in on AGTC. HC Wainwright reiterated a “buy” rating and issued a $5.75 price target on shares of Applied Genetic Technologies in a research report on Friday. BMO Capital Markets downgraded shares of Applied Genetic Technologies from an “outperform” rating to a “market perform” rating and set a $5.00 price target on the stock. in a research report on Thursday, December 13th. Zacks Investment Research upgraded shares of Applied Genetic Technologies from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research report on Wednesday, November 14th. ValuEngine downgraded shares of Applied Genetic Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, December 13th. Finally, TheStreet downgraded shares of Applied Genetic Technologies from a “c-” rating to a “d+” rating in a research report on Wednesday, January 2nd. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $7.55.

WARNING: This article was published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/4139500/applied-genetic-technologies-agtc-releases-quarterly-earnings-results-beats-estimates-by-0-41-eps.html.

Applied Genetic Technologies Company Profile

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.

See Also: Should You Consider an Index Fund?

Earnings History for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Orbis Token  Tops 24 Hour Volume of $0.00
Orbis Token Tops 24 Hour Volume of $0.00
RichCoin Price Up 13.8% Over Last Week
RichCoin Price Up 13.8% Over Last Week
Analysts Expect Osmotica Pharmaceuticals PLC  to Post $0.20 Earnings Per Share
Analysts Expect Osmotica Pharmaceuticals PLC to Post $0.20 Earnings Per Share
CNO Financial Group Inc  Receives Average Recommendation of “Hold” from Brokerages
CNO Financial Group Inc Receives Average Recommendation of “Hold” from Brokerages
indaHash Trading 4.6% Higher  Over Last Week
indaHash Trading 4.6% Higher Over Last Week
Mercury General Co.  Receives Consensus Rating of “Sell” from Analysts
Mercury General Co. Receives Consensus Rating of “Sell” from Analysts


Leave a Reply

© 2006-2019 Ticker Report